Prodrugs for phosphorus-containing compounds

Details Prodrugs for phosphorus-containing compounds Prodrugs for phosphorus-containing compounds

2005-09-20

2005-09-20

Jones, Dameron L. (Department: 1616)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

C424S001110, C424S001650, C424S600000, C424S601000

Reexamination Certificate

active

06946115

ABSTRACT:
Prodrugs of formula I, their uses, their intermediates, and their method of manufacturing are described:and pharmaceutically acceptable prodrugs and salts thereof.

REFERENCES:
patent: 3018302 (1962-01-01), Bielefeld et al.
patent: 5658889 (1997-08-01), Gruber et al.
patent: 6054587 (2000-04-01), Reddy et al.
patent: 6110903 (2000-08-01), Kasibhatla et al.
patent: 6284748 (2001-09-01), Dang et al.
patent: 6294672 (2001-09-01), Reddy et al.
patent: 6312662 (2001-11-01), Erion et al.
patent: 6399782 (2002-06-01), Kasibhatla et al.
patent: 6489476 (2002-12-01), Dang et al.
patent: 3512781 (1985-04-01), None
patent: 0 161 955 (1985-11-01), None
patent: 0 180 276 (1986-05-01), None
patent: 0 338 372 (1989-10-01), None
patent: 0 353 692 (1990-02-01), None
patent: 0 481 214 (1992-04-01), None
patent: 91 19721 (1991-12-01), None
patent: WO 96/01267 (1996-01-01), None
patent: WO 97/03679 (1997-02-01), None
patent: 98 39342 (1998-11-01), None
patent: 98 39343 (1998-11-01), None
patent: 98 39344 (1998-11-01), None
Alexander, et al., “Preparation of 9-(2-Phosphonomethoxyethyl) Adenine Esters as Potential Prodrugs,” Colect. Czech, Chem Commun., 59: 1853-1869 (1994).
Amin, et al., “1-Hydroxy-3-(methylpentylamino)-propylidene-1, 1-bisphosphonic Acid as a Potent Inhibitor o Squalene Synthase,”Apznemittelforschung. 46(8): 759-762 (1996).
Atiq, O.T., et al., “Treatment of Unresectable Primary Liver cancer With Intrahepatic Fluorodeoxyuridine an Mitomycin C Through and Implantable Pump,”Cancer, 69, 920-924 (1992).
Auberson, et al., “N-Phosphoalkyl-5-Aminomethylquinoxaline-2,3-Diones: In Vivo Active Ampa and NMDA(Glycine) Antagonists,”Bioorg. Med. Chem. Lett., 9: 249-254 (1999).
Balthazor, et al. “Nickel-Catalyzed Arbuzov Reaction: Mechanistic Observation,”J. Org Chem., 45: 5425-5426 (1980).
He, et al., “Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice,”Chem Res. Toxicol1998, 11, 252-259.
Bespalov, et al., “Prologation of morphine analgesia by competitive NMDA receptor antagonist D-CPPene (SDZ EAA 494) in rats,”Eur. J. Pharmacol. 351: 299-305 (1998).
Bijsterbosch, et al., “Disposition of the acyclic Nucleoside Phosphonate (S)-9-(3-Hydroxy-2-Phosphonylmethoxypropyl) Adenine,”Antimicrobial Agents and Chemotherapy. 42(5): 1146-1150 (1998).
Bird, et al., “Synthesis of Novel N-Phosphonoalkyl Dipeptide Inhibitors of Human Collagenase,”J. Med. Chem. 73: 158-169 (1994).
Brill and Landon, et al.,Chem Rev., 84: 577-585 (1984).
Campagne, et al. “Synthesis of Mixed Phosphate Diester Analogues of Dipeptides using BOP or PyBOP Reagents,”Tetrahedron Lett., 34(42): 6743-6744 (1993).
Campbell, “The Synthesis of Phosphonate Esthers, an Extension of the Mitsunobu Reation”,J. Org. Chem. 52: 6331-6335 (1992).
Casara, et al., “Synthesis of Acid Stable 5′-o-Fluorometer Phosphonates of Nucleosides,”Bioorg. Med. Chem Lett., 2(2): 145-148 (1992).
Casteel, et al., “Steric and Electronic Effects in the Aryl Phosphate to Arylphoshonate Rearrangement,”Synthesis, 691-693 (1991).
Chen, et al., , “Sensitization of Human Breast Cancer Cels to Cyclophosphamide and Ifosfamide by Transfer of al Liver Cytochrome P450 Gene,”Cancer Research, 56, 1331-1340 (1996).
Chen and Waxman “Intratumoral Activation and Enhanced Chemotheraputic Effect of Oxazaphosphorines following Cytochrome P-450 Gene Transfer: Development of a Combined chemptherapy/Cancer Gene Therapy Strategy,”Cancer Research, 55, 581-589 (1995).
De Lombaert, et al., “N-Phosphomomethgyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors”J. Med. Chem37: 498-511 (1994).
De Lombaert, et al., “Pharmacological profile of a Non-Peptidic Dual Inhibitor of Neutral Endopeptidase 24.11 and Endothelin-converting enzyme,”Biochem Biophys Res Commun204: 407-412 (1994).
De Waziers, et al., “Cytochrome P 450 Isoenzymes, Epoxide Hydrolase and Glutathione Transferases in Rat and Human Hepatic and Extrahepatic Tissues,”J. Pharm. Exp. Ther. 253: 387-394 (1990).
Dearfield, et al., “Analysis of the Genotoxicity of Nine Acrylate/Methacrylate Coumpounds in L5178Y Mouse Lymphoma Cells,”Mutagenisis4: 381-393 (1989).
Desos, et al., “Structure-Activity Relationships in a Series of 2(1H)-Quinolones Bearing Different Acidic Function in the 3-Position: 6,7-Dichloro-2(1H)-oxoquinoline-3-phosphonic Acid, a New Potent and Selectiv AMPA/Kainate Antagonist with Neuroprotective Properties,” 39: 197-206 (1996).
Dickson, et al., “Orally Active Squalene Synthase Inhibitors: Bis((acyloxy)alkyl) Prodrugs of the α-Phosphonosulfonic Acid Moiety,”J. Med. Chem. 39: 661-664 (1996).
Edmunson, et al., “Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2λ5-dioxaphosphorinane Series. X-Ray Molecular Structure of cis-2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-Oxide,”J. Chem. Res. Synop., 5: 122-123 (1989).
Enriquez, et al., “Conjugation of Aadenine Arabinoside 5′-Monophosphate to Arabinogalactan: Synthesis, Characterization, and Antiviral Activity,”Bioconjugate Chem. 6: 195-202 (1995).
Farquhar, et al. “Biologically-Cleavable Phosphate Protective Groups: 4-Aclioxt-1,3,2-Dioxaphosphorinanes as Neutral Latent Precursors of Dianionic Phosphates,”Tetrahedron Lett., 36(5): 655-658 (1995).
Farquhar, et al., “Biologically Reversible Phosphate-Protective Groups,”Journal of Pharmaceutical Sciences72(3): 324-325 (1983).
Farquhar, et al. “Synthesis and Biological Evaluation of 9-[5′-(2-Oxo-1,3,2-oxazaphosphorinan-2-yl)-β-D-arabinosyl]adenine and 9-[5′-(2-Oxo-1,3,2-dioxazaphosphorinan-2-yl)-β-D-arabinosyl]adenine: Potential Neutral Precursors of 9-[β-D-Arabinofuranosyl]adenine 5′-Monophosphate,”J. Med. Chem. 28: 1358-1361 (1985).
Farquhar, et al., “Synthesis and Biological Evaluation of Neutral Derivatives of 5-Fluoro-2′-deoxyuridine 5′-Phosphate,”J. Med. Chem. 26: 1153-1158 (1983).
Fiume, et al.,“Inhibition of Hepatitis B Virus replication By Vidarbine Monophosphate Conjugated with Lactosaminated Serum Albumin,”The Lancet13-15 (1988).
Freed, et al., “Evidence for Acyloxymethyyl Esters of Pyridmidenc, 5′-Deoxyribonucleotides as extraceullar sources of active a5′-deozyriboinucleotides in cultured cells,” Biochemical Pharmacology, 38(19): 3193-3198 (1989).
Guida, et al.,“Structure-Based Design of Inhibitors of Purine Nucleoside Phosphorylase. 4. A Study of Phosphate Mimics,”J. Med. Chem. 37: 1109-1114 (1994).
Hirayama, et al., “Structure and conformation of a novel inhibitor of angiotensin I converting enzyme—a tripeptide containing phosphonic acid,”Int. J. Pept. Protein Res. 38: 20-24 (1991).
Hunston, et al., “Synthesis and Biological Properties of Some Cyclic Phosphotriesters Derived from 2′-Deoxy-5-fluorouridine,”J. Med. Chem. 27: 440-444 (1984).
Keenan, et al., “Pathology Reevaluation of the Kociba et al. (1978) Bioassay of 2,3,7,8-TCDD: Implications for Risk Assessment,”J. Tox. Envir. Health34: 279-296 (1991).
Kelley, et al., “[[(Guaninylalkl) phosphinico]methyl] phosphonic Acids. Multisubstrate Analogue inhibitors o Human Erythrocyte Purine Nucleoside Phosphorylase,”J. Med. Chem. 38: 1005-1014 (1995).
Khamnei and Torrence, “Neighboring Group Catalysis in the Design of Nucleotide Prodrugs,”J. Med. Chem. 39: 4109-4115 (1996).
Kryuchkov, et al.,Izv. Akad. Nauk SSSR, Ser. Khim. 6: 1201-1248 (1987).
Lok, et al., “Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection,”J. Antimicrob. Chemotherap. 14: 93-99 (1984).
Lu et al., Palladiu

Affiliated with

Also associated with

Rating

Prodrugs for phosphorus-containing compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prodrugs for phosphorus-containing compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs for phosphorus-containing compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3449992